Challenges in the management of serious infections in pediatric patients

Pediatric Infectious Disease Journal

Volumn 15, Issue 8, 1996, Pages 729-732

  Adam, Dieter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

carbapenems; imipenem cilastatin; Infection; meropenem

Indexed keywords

CARBAPENEM; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; CHILD; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFICACY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CHILD; DRUG THERAPY, COMBINATION; HUMANS;

EID: 0029740626     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199608000-00033     Document Type: Conference Paper

References (23)

1. Buchanan N. Paediatric clinical pharmacology and therapeutics. In: Speight TM, ed. Avery's drug treatment: principles and practice of clinical pharmacology and therapeutics. 3rd ed., Auckland, New Zealand: Adis Press, 1987: 118-59.
2. Reed MD. Principles of drug therapy. In: Behrman RE, Kliegman RM, Nelson E, Vaughan VC III. Textbook of pediatrics. 14th ed. Philadelphia: Saunders, 1992:252-8.
3. Wong AF, Cupit GC. Neonatal therapy. In: Koda-Kimble MA, Young LY. Applied therapeutics: the clinical use of drugs. Vancouver, Canada: Applied Therapeutics Inc., 1992:78.1-78.18.
4. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate: a critical evaluation of the pharmaco-kinetic-pharmacodynamic interface (Part 1). Clin Pharmacokinet 1988;14:189-216.
5. Vaughan VC III, Litt IS. The newborn infant. In: Behrman RE, Kliegman RM, Nelson E, Vaughan VC III. Textbook of pediatrics. 14th ed. Philadelphia: Saunders, 1992:15-8.
6. Schutze GE, Kaplan SL, Jacobs RF. Resistant pneumococcus: a worldwide problem. Infection 1994;22:233-9.
7. Boyce JM. Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Microbiol Infect Dis 1994;13:45-9.
8. Rupp ME, Archer GL. Coagulase-negative staphylococci: pathogens associated with medical progress. Clin Infect Dis 1994;19:231-43.
9. Sanders CC, Sanders WE. Beta-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824-39.
10. Nicoletti G, Stefani S. Enterococci: susceptibility patterns and therapeutic options. Eur J Clin Microbiol Infect Dis 1995;14(Suppl 1):33-7.
11. Blumer JL. Carbapenems in pediatrics. Scand J Infect Dis 1995;Suppl 96:38-44.
12. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(Suppl A):1-17.
13. Blumer JL. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J 1996; 15:733-7.
14. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991;10:918-23.
15. Boogaerts MA, Demuynck H, Mestdagh N. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
16. Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/ cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44: 408-44.
17. Norrby SR, Vandercam B, Louie T, et al. Imipenem-cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scand J Infect Dis 1987;Suppl 52:65-78.
18. Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
19. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50:73-101.
20. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36(Suppl 4):207-23.
21. Bradley JS, Faulkner KL, Klugman KP. Meropenem: tolerability and efficacy as empirical antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996;15:749-57.
22. Cometta A, Viscoli C, Castagnola E, et al. Empirical treatment of fever in neutropenic children: the role of carbapenems. Pediatr Infect Dis J 1996;15:744-8.
23. Høiby N, Ciofu O, Jensen T, Pressler T, Johansen HK. Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis. Pediatr Infect Dis J 1996;15: 738-43.